Cullinan Therapeutics, Inc. 8-K

What Happened
On May 7, 2026 Cullinan Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 and furnished the company press release as Exhibit 99.1 to a Form 8-K (Item 2.02). The report was signed by Mary Kay Fenton, Chief Financial Officer.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 contains the detailed quarterly results and is available with the 8-K filing.
• The Form 8-K primarily furnishes the earnings press release; no other material corporate actions (e.g., executive changes, mergers) were reported in this filing.

Why It Matters
This 8-K signals Cullinan publicly disclosed its quarterly earnings and related financial condition; investors should review the Exhibit 99.1 press release for revenue, net income/loss, cash position, and any management commentary or guidance. Quarterly results can affect the stock and investor expectations, so retail investors monitoring earnings, revenue trends, or liquidity for biotech companies should read the press release and any subsequent SEC filings for full financial detail.